PMD DEVICE SOLUTIONS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.65 SEK | -0.75% |
|
-20.36% | -40.65% |
Presenter SpeechAlf Riple (Analysts)Good morning and very welcome to this presentation of Prom...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
Calendar
2024-06-28
- Annual General Meeting
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.65% | 13.26M | |
| +14.33% | 118B | |
| +13.66% | 106B | |
| -2.20% | 24.28B | |
| +0.76% | 21.96B | |
| -8.96% | 18.16B | |
| -42.12% | 16.37B | |
| -16.79% | 15.56B | |
| +5.99% | 13.63B | |
| +29.48% | 12.27B |
- Stock Market
- Equities
- PMDS Stock
- News PMD Device Solutions AB
- Transcript : Promore Pharma AB, Q3 2020 Earnings Call, Nov 25, 2020
